000289286 001__ 289286
000289286 005__ 20250731112615.0
000289286 0247_ $$2doi$$a10.1002/ijc.34919
000289286 0247_ $$2pmid$$apmid:38577820
000289286 0247_ $$2ISSN$$a0020-7136
000289286 0247_ $$2ISSN$$a1097-0215
000289286 0247_ $$2altmetric$$aaltmetric:161568764
000289286 037__ $$aDKFZ-2024-00681
000289286 041__ $$aEnglish
000289286 082__ $$a610
000289286 1001_ $$aSingini, Mwiza Gideon$$b0
000289286 245__ $$aAntibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
000289286 260__ $$aBognor Regis$$bWiley-Liss$$c2024
000289286 3367_ $$2DRIVER$$aarticle
000289286 3367_ $$2DataCite$$aOutput Types/Journal article
000289286 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1716279867_2024
000289286 3367_ $$2BibTeX$$aARTICLE
000289286 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289286 3367_ $$00$$2EndNote$$aJournal Article
000289286 500__ $$a2024 Jul 15;155(2):251-260
000289286 520__ $$aHuman papillomavirus (HPV) proteins may elicit antibody responses in the process toward HPV-related malignancy. However, HPV seroepidemiology in noncervical HPV-related cancers remains poorly understood, particularly in populations with a high prevalence of human immunodeficiency virus (HIV). Using a glutathione S-transferase-based multiplex serology assay, antibodies against E6, E7 and L1 proteins of HPV16 and HPV18 were measured in sera of 535 cases of noncervical HPV-related cancers (anal (n = 104), vulval (n = 211), vaginal (n = 49), penile (n = 37) and oropharyngeal (n = 134)) and 6651 non-infection-related cancer controls, from the Johannesburg Cancer Study that recruited Black South African with newly diagnosed cancer between 1995 and 2016. Logistic and Poisson regression models were used to calculate adjusted odds ratios (aOR) and prevalence ratios (aPR) and 95% confidence intervals (CI) in cases versus controls. HPV16 E6 was more strongly associated with noncervical HPV-related cancers than HPV16 L1 or E7, or HPV18 proteins: anal (females (HPV16 E6 aOR = 11.50;95%CI:6.0-22.2), males (aOR = 10.12;95%CI:4.9-20.8), vulval (aOR = 11.69;95%CI:7.9-17.2), vaginal (aOR = 10.26;95%CI:5.0-21), penile (aOR = 18.95;95%CI:8.9-40), and oropharyngeal (females (aOR = 8.95;95%CI:2.9-27.5), males (aOR = 3.49;95%CI:1.8-7.0)) cancers. HPV16-E6 seropositivity ranged from 24.0% to 35.1% in anal, vulval, vaginal and penile cancer but was significantly lower (11.2%) in oropharyngeal cancer. After adjustment for HIV, prevalence of which increased from 22.2% in 1995-2005 to 54.1% in 2010-2016, HPV16 E6 seropositivity increased by period of diagnosis (aPR for 2010-2016 vs. 1995-2006 = 1.84;95%CI:1.1-3.0). Assuming HPV16 E6 seroprevalence reflects HPV attributable fraction, the proportion of certain noncervical-HPV-related cancers caused by HPV is increasing over time in South Africa. This is expected to be driven by the increasing influence of HIV.
000289286 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000289286 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289286 650_7 $$2Other$$aBlack South African
000289286 650_7 $$2Other$$aHIV status
000289286 650_7 $$2Other$$ahuman papillomavirus
000289286 650_7 $$2Other$$anoncervical HPV‐related cancers
000289286 650_7 $$2Other$$aproteins
000289286 7001_ $$00000-0002-1955-923X$$aMuchengeti, Mazvita$$b1
000289286 7001_ $$aSitas, Freddy$$b2
000289286 7001_ $$aChen, Wenlong Carl$$b3
000289286 7001_ $$aCombes, Jean-Damien$$b4
000289286 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b5$$udkfz
000289286 7001_ $$aClifford, Gary M$$b6
000289286 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34919$$gp. ijc.34919$$n2$$p251-260$$tInternational journal of cancer$$v155$$x0020-7136$$y2024
000289286 8564_ $$uhttps://inrepo02.dkfz.de/record/289286/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Singini%20-%20Antibodies%20against%20high%E2%80%90risk%20human%20papillomavirus%20proteins%20as%20markers%20for.pdf
000289286 8564_ $$uhttps://inrepo02.dkfz.de/record/289286/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Singini%20-%20Antibodies%20against%20high%E2%80%90risk%20human%20papillomavirus%20proteins%20as%20markers%20for.pdf?subformat=pdfa$$xpdfa
000289286 909CO $$ooai:inrepo02.dkfz.de:289286$$pVDB
000289286 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289286 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000289286 9141_ $$y2024
000289286 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000289286 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000289286 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000289286 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000289286 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x0
000289286 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x1
000289286 980__ $$ajournal
000289286 980__ $$aVDB
000289286 980__ $$aI:(DE-He78)F020-20160331
000289286 980__ $$aI:(DE-He78)D320-20160331
000289286 980__ $$aUNRESTRICTED